DA Davidson analyst Linda Bolton Weiser upgraded Medifast (MED) to Neutral from Underperform with a price target of $17, up from $16.50. With cash and investments of about $15.50 per share and no debt, the valuation “already seems to imply near zero for the remaining declining business,” so share price downside could be more limited from here, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MED: